Acute Crit Care.  2019 Feb;34(1):14-29. 10.4266/acc.2019.00430.

Medical Management of Brain-Dead Organ Donors

• Anwar AT
• Lee JM

• KMID: 2449376
• DOI: http://doi.org/10.4266/acc.2019.00430

Abstract

With improving healthcare services, the demand for organ transplants has been increasing daily worldwide. Deceased organ donors serve as a good alternative option to meet this demand. The first step in this process is identifying potential organ donors. Specifically, brain-dead patients require aggressive and intensive care from the declaration of brain death until organ retrieval. Currently, there are no specific protocols in place for this, and there are notable variations in the management strategies implemented across different transplant centers. Some transplant centers follow their own treatment protocols, whereas other countries, such as Bangladesh, do not have any protocols for potential organ donor care. In this review, we discuss how to identify brain-dead donors and describe the physiological changes that occur following brain death. We then summarize the management of brain-dead organ donors and, on the basis of a review of the literature, we propose recommendations for a treatment protocol to be developed in the future.

Keyword

brain death; intensive care; organ donation

MeSH Terms

Bangladesh
Brain Death
Clinical Protocols
Critical Care
Delivery of Health Care
Humans
Tissue and Organ Harvesting
Tissue and Organ Procurement
Tissue Donors*
Transplants

Reference

1. Kutsogiannis DJ, Pagliarello G, Doig C, Ross H, Shemie SD. Medical management to optimize donor organ potential: review of the literature. Can J Anaesth. 2006; 53:820–30.

2. McKeown DW, Bonser RS, Kellum JA. Management of the heartbeating brain-dead organ donor. Br J Anaesth. 2012; 108 Suppl 1:i96–107.

3. Bos EM, Leuvenink HG, van Goor H, Ploeg RJ. Kidney grafts from brain dead donors: inferior quality or opportunity for improvement? Kidney Int. 2007; 72:797–805.

4. Rodrigues Sde L, Ferraz Neto JB, Sardinha LA, Araujo S, Zambelli HJ, Boin Ide F, et al. Profile of effective donors from organ and tissue procurement services. Rev Bras Ter Intensiva. 2014; 26:21–7.

5. Wood KE, Becker BN, McCartney JG, D’Alessandro AM, Coursin DB. Care of the potential organ donor. N Engl J Med. 2004; 351:2730–9.

6. Goila AK, Pawar M. The diagnosis of brain death. Indian J Crit Care Med. 2009; 13:7–11.

7. de Groot YJ, Jansen NE, Bakker J, Kuiper MA, Aerdts S, Maas AI, et al. Imminent brain death: point of departure for potential heart-beating organ donor recognition. Intensive Care Med. 2010; 36:1488–94.

8. Dhanwate AD. Brainstem death: a comprehensive review in Indian perspective. Indian J Crit Care Med. 2014; 18:596–605.

9. Wikipedia contributors. Brain death [Internet]. San Francisco (CA): Wikimedia Foundation;[cited 2019 Feb 20]. Available from: https://en.wikipedia.org/wiki/Brain_death.

10. Karasawa H, Sakaida K, Noguchi S, Hatayama K, Naito H, Hirota N, et al. Intracranial electroencephalographic changes in deep anesthesia. Clin Neurophysiol. 2001; 112:25–30.

11. Young GB. Diagnosis of brain death [Internet]. Waltham (MA): UpToDate;2018. [cited 2019 Feb 20]. Available from: https://www.uptodate.com/contents/diagnosis-of-brain-death.

12. Kotloff RM, Blosser S, Fulda GJ, Malinoski D, Ahya VN, Angel L, et al. Management of the potential organ donor in the ICU: Society of Critical Care Medicine/American College of Chest Physicians/Association of Organ Procurement Organizations Consensus Statement. Crit Care Med. 2015; 43:1291–325.

13. Hahnenkamp K, Böhler K, Wolters H, Wiebe K, Schneider D, Schmidt HH. Organ-protective intensive care in organ donors. Dtsch Arztebl Int. 2016; 113:552–8.

14. Powner DJ, Darby JM, Kellum JA. Proposed treatment guidelines for donor care. Prog Transplant. 2004; 14:16–26.

15. Smith M. Physiologic changes during brain stem death: lessons for management of the organ donor. J Heart Lung Transplant. 2004; 23(9 Suppl):S217–22.

16. Amado JA, López-Espadas F, Vázquez-Barquero A, Salas E, Riancho JA, López-Cordovilla JJ, et al. Blood levels of cytokines in brain-dead patients: relationship with circulating hormones and acute-phase reactants. Metabolism. 1995; 44:812–6.

17. Mascia L, Mastromauro I, Viberti S, Vincenzi M, Zanello M. Management to optimize organ procurement in brain dead donors. Minerva Anestesiol. 2009; 75:125–33.

18. Rey JW, Ott T, Bösebeck D, Welschehold S, Galle PR, Werner C. Organ protective intensive care treatment and simulationbased training. Anaesthesist. 2012; 61:242–8.

19. Rech TH, Moraes RB, Crispim D, Czepielewski MA, Leitão CB. Management of the brain-dead organ donor: a systematic review and meta-analysis. Transplantation. 2013; 95:966–74.

20. Wong J, Tan HL, Goh JP. Management of the brain dead organ donor. Trends Anaesth Crit Care. 2017; 13:6–12.

21. Kumar L. Brain death and care of the organ donor. J Anaesthesiol Clin Pharmacol. 2016; 32:146–52.

22. Szabó G, Hackert T, Sebening C, Vahl CF, Hagl S. Modulation of coronary perfusion pressure can reverse cardiac dysfunction after brain death. Ann Thorac Surg. 1999; 67:18–25.

23. Venkateswaran RV, Patchell VB, Wilson IC, Mascaro JG, Thompson RD, Quinn DW, et al. Early donor management increases the retrieval rate of lungs for transplantation. Ann Thorac Surg. 2008; 85:278–86.

24. Avlonitis VS, Fisher AJ, Kirby JA, Dark JH. Pulmonary transplantation: the role of brain death in donor lung injury. Transplantation. 2003; 75:1928–33.

25. Novitzky D, Wicomb WN, Rose AG, Cooper DK, Reichart B. Pathophysiology of pulmonary edema following experimental brain death in the chacma baboon. Ann Thorac Surg. 1987; 43:288–94.

26. Strieter RM, Kunkel SL. Acute lung injury: the role of cytokines in the elicitation of neutrophils. J Investig Med. 1994; 42:640–51.

27. de Vries DK, Lindeman JH, Ringers J, Reinders ME, Rabelink TJ, Schaapherder AF. Donor brain death predisposes human kidney grafts to a proinflammatory reaction after transplantation. Am J Transplant. 2011; 11:1064–70.

28. Bugge JF. Brain death and its implications for management of the potential organ donor. Acta Anaesthesiol Scand. 2009; 53:1239–50.

29. Novitzky D, Cooper DK, Rosendale JD, Kauffman HM. Hormonal therapy of the brain-dead organ donor: experimental and clinical studies. Transplantation. 2006; 82:1396–401.

30. Gramm HJ, Meinhold H, Bickel U, Zimmermann J, von Hammerstein B, Keller F, et al. Acute endocrine failure after brain death? Transplantation. 1992; 54:851–7.

31. Howlett TA, Keogh AM, Perry L, Touzel R, Rees LH. Anterior and posterior pituitary function in brain-stem-dead donors: a possible role for hormonal replacement therapy. Transplantation. 1989; 47:828–34.

32. Tien RD. Sequence of enhancement of various portions of the pituitary gland on gadolinium-enhanced MR images: correlation with regional blood supply. AJR Am J Roentgenol. 1992; 158:651–4.

33. Blasi-Ibanez A, Hirose R, Feiner J, Freise C, Stock PG, Roberts JP, et al. Predictors associated with terminal renal function in deceased organ donors in the intensive care unit. Anesthesiology. 2009; 110:333–41.

34. Barklin A. Systemic inflammation in the brain-dead organ donor. Acta Anaesthesiol Scand. 2009; 53:425–35.

35. Murugan R, Venkataraman R, Wahed AS, Elder M, Hergenroeder G, Carter M, et al. Increased plasma interleukin-6 in donors is associated with lower recipient hospital-free survival after cadaveric organ transplantation. Crit Care Med. 2008; 36:1810–6.

36. Pandit RA, Zirpe KG, Gurav SK, Kulkarni AP, Karnath S, Govil D, et al. Management of potential organ donor: Indian Society of Critical Care Medicine: position statement. Indian J Crit Care Med. 2017; 21:303–16.

37. Talving P, Benfield R, Hadjizacharia P, Inaba K, Chan LS, Demetriades D. Coagulopathy in severe traumatic brain injury: a prospective study. J Trauma. 2009; 66:55–61.

38. Barklin A, Tønnesen E, Ingerslev J, Sørensen B, Fenger-Eriksen C. Coagulopathy during induced severe intracranial hypertension in a porcine donor model. Anesthesiology. 2009; 110:1287–92.

39. Intensive Care Society of Ireland. Diagnosis of brain death & medical management of the organ donor: guidelines for adult patients [Internet]. Intensive Care Society of Ireland;2010. [cited 2019 Feb 20]. Available from: https://www.anaesthesia.ie/archive/ICSI/ICSI%20Guidelines%20MAY10.pdf.

40. Gelb AW, Robertson KM. Anaesthetic management of the brain dead for organ donation. Can J Anaesth. 1990; 37:806–12.

41. Franklin GA, Santos AP, Smith JW, Galbraith S, Harbrecht BG, Garrison RN. Optimization of donor management goals yields increased organ use. Am Surg. 2010; 76:587–94.

42. Selck FW, Deb P, Grossman EB. Deceased organ donor characteristics and clinical interventions associated with organ yield. Am J Transplant. 2008; 8:965–74.

43. Klein AS, Messersmith EE, Ratner LE, Kochik R, Baliga PK, Ojo AO. Organ donation and utilization in the United States, 1999-2008. Am J Transplant. 2010; 10(4 Pt 2):973–86.

44. Wood KE, McCartney J. Management of the potential organ donor. Transplant Rev. 2007; 21:204–18.

45. Shemie SD, Ross H, Pagliarello J, Baker AJ, Greig PD, Brand T, et al. Organ donor management in Canada: recommendations of the forum on Medical Management to Optimize Donor Organ Potential. CMAJ. 2006; 174:S13–32.

46. Nygaard CE, Townsend RN, Diamond DL. Organ donor management and organ outcome: a 6-year review from a Level I trauma center. J Trauma. 1990; 30:728–32.

47. Wood KE, Coursin DB. Intensivists and organ donor management. Curr Opin Anaesthesiol. 2007; 20:97–9.

48. Rona G. Catecholamine cardiotoxicity. J Mol Cell Cardiol. 1985; 17:291–306.

49. Avlonitis VS, Wigfield CH, Kirby JA, Dark JH. The hemodynamic mechanisms of lung injury and systemic inflammatory response following brain death in the transplant donor. Am J Transplant. 2005; 5(4 Pt 1):684–93.

50. Plurad DS, Bricker S, Falor A, Neville A, Bongard F, Putnam B. Donor hormone and vasopressor therapy: closing the gap in a transplant organ shortage. J Trauma Acute Care Surg. 2012; 73:689–94.

51. Plurad DS, Bricker S, Neville A, Bongard F, Putnam B. Arginine vasopressin significantly increases the rate of successful organ procurement in potential donors. Am J Surg. 2012; 204:856–60.

52. Callahan DS, Neville A, Bricker S, Kim D, Putnam B, Bongard F, et al. The effect of arginine vasopressin on organ donor procurement and lung function. J Surg Res. 2014; 186:452–7.

53. Pennefather SH, Bullock RE, Mantle D, Dark JH. Use of low dose arginine vasopressin to support brain-dead organ donors. Transplantation. 1995; 59:58–62.

54. Chen JM, Cullinane S, Spanier TB, Artrip JH, John R, Edwards NM, et al. Vasopressin deficiency and pressor hypersensitivity in hemodynamically unstable organ donors. Circulation. 1999; 100(19 Suppl):II244-6.

55. Di Giantomasso D, May CN, Bellomo R. Norepinephrine and vital organ blood flow. Intensive Care Med. 2002; 28:1804–9.

56. Di Giantomasso D, Morimatsu H, Bellomo R, May CN. Effect of low-dose vasopressin infusion on vital organ blood flow in the conscious normal and septic sheep. Anaesth Intensive Care. 2006; 34:427–33.

57. Weiner N. Norepinephrine, epinephrine, and sympathomimetic amines. In : Gilman AC, Goodman LS, Rall TW, Murad F, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. 6th ed. New York: MacMillan;1985. p. 145–80.

58. Novitzky D, Cooper DK, Wicomb WM, Reichert B. Haemodynamic changes, myocardial injury, and pulmonary oedema induced by sympathetic activity during the development of brain death in the baboon. Transplant Proc. 1986; 13:609–12.

59. Yoshioka T, Sugimoto H, Uenishi M, Sakamoto T, Sadamitsu D, Sakano T, et al. Prolonged hemodynamic maintenance by the combined administration of vasopressin and epinephrine in brain death: a clinical study. Neurosurgery. 1986; 18:565–7.

60. Findlater C, Thomson EM. Organ donation and management of the potential organ donor. Anaesth Intensive Care Med. 2015; 16:315–20.

61. Mi Z, Novitzky D, Collins JF, Cooper DK. The optimal hormonal replacement modality selection for multiple organ procurement from brain-dead organ donors. Clin Epidemiol. 2014; 7:17–27.

62. Logigian EL, Ropper AH. Terminal electrocardiographic changes in brain-dead patients. Neurology. 1985; 35:915–8.

63. Vaghadia H. Atropine resistance in brain-dead organ donors. Anesthesiology. 1986; 65:711–2.

64. Mascia L, Pasero D, Slutsky AS, Arguis MJ, Berardino M, Grasso S, et al. Effect of a lung protective strategy for organ donors on eligibility and availability of lungs for transplantation: a randomized controlled trial. JAMA. 2010; 304:2620–7.

65. Rosendale JD, Kauffman HM, McBride MA, Chabalewski FL, Zaroff JG, Garrity ER, et al. Aggressive pharmacologic donor management results in more transplanted organs. Transplantation. 2003; 75:482–7.

66. Goarin JP, Cohen S, Riou B, Jacquens Y, Guesde R, Le Bret F, et al. The effects of triiodothyronine on hemodynamic status and cardiac function in potential heart donors. Anesth Analg. 1996; 83:41–7.

67. Novitzky D, Cooper DK, Morrell D, Isaacs S. Change from aerobic to anaerobic metabolism after brain death, and reversal following triiodothyronine therapy. Transplantation. 1988; 45:32–6.

68. Novitzky D, Wicomb WN, Cooper DK, Tjaalgard MA. Improved cardiac function following hormonal therapy in brain dead pigs: relevance to organ donation. Cryobiology. 1987; 24:1–10.

69. Randell TT, Höckerstedt KA. Triiodothyronine treatment is not indicated in brain-dead multiorgan donors: a controlled study. Transplant Proc. 1993; 25(1 Pt 2):1552–3.

70. Masson F, Thicoïpe M, Latapie MJ, Maurette P. Thyroid function in brain-dead donors. Transpl Int. 1990; 3:226–33.

71. Zaroff JG, Rosengard BR, Armstrong WF, Babcock WD, D’Alessandro A, Dec GW, et al. Consensus conference report: maximizing use of organs recovered from the cadaver donor: cardiac recommendations, March 28-29, 2001, Crystal City, Va. Circulation. 2002; 106:836–41.

72. Salim A, Vassiliu P, Velmahos GC, Sava J, Murray JA, Belzberg H, et al. The role of thyroid hormone administration in potential organ donors. Arch Surg. 2001; 136:1377–80.

73. Novitzky D, Cooper DK, Reichart B. Hemodynamic and metabolic responses to hormonal therapy in brain-dead potential organ donors. Transplantation. 1987; 43:852–4.

74. Rosendale JD, Chabalewski FL, McBride MA, Garrity ER, Rosengard BR, Delmonico FL, et al. Increased transplanted organs from the use of a standardized donor management protocol. Am J Transplant. 2002; 2:761–8.

75. Kotsch K, Ulrich F, Reutzel-Selke A, Pascher A, Faber W, Warnick P, et al. Methylprednisolone therapy in deceased donors reduces inflammation in the donor liver and improves outcome after liver transplantation: a prospective randomized controlled trial. Ann Surg. 2008; 248:1042–50.

76. McLean KM, Duffy JY, Pandalai PK, Lyons JM, Bulcao CF, Wagner CJ, et al. Glucocorticoids alter the balance between proand anti-inflammatory mediators in the myocardium in a porcine model of brain death. J Heart Lung Transplant. 2007; 26:78–84.

77. Kainz A, Wilflingseder J, Mitterbauer C, Haller M, Burghuber C, Perco P, et al. Steroid pretreatment of organ donors to prevent postischemic renal allograft failure: a randomized, controlled trial. Ann Intern Med. 2010; 153:222–30.

78. Chamorro C, Falcón JA, Michelena JC. Controversial points in organ donor management. Transplant Proc. 2009; 41:3473–5.

79. Singer P, Cohen J, Cynober L. Effect of nutritional state of braindead organ donor on transplantation. Nutrition. 2001; 17:948–52.

80. Singer P, Shapiro H, Cohen J. Brain death and organ damage: the modulating effects of nutrition. Transplantation. 2005; 80:1363–8.

81. Najafizadeh K, Arab M, Radpei B, Pojhan S, Abbasi-Dezfuli A, Deneshvar A, et al. Age and sex predict PaO₂/FiO₂ ratio in brain-dead donor lungs. Transplant Proc. 2009; 41:2720–2.

82. Van Raemdonck D, Neyrinck A, Verleden GM, Dupont L, Coosemans W, Decaluwé H, et al. Lung donor selection and management. Proc Am Thorac Soc. 2009; 6:28–38.

83. Zafar F, Khan MS, Heinle JS, Adachi I, McKenzie ED, Schecter MG, et al. Does donor arterial partial pressure of oxygen affect outcomes after lung transplantation? A review of more than 12,000 lung transplants. J Thorac Cardiovasc Surg. 2012; 143:919–25.